GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors

详细信息    查看全文

• 作者：Yuqiong Yang ; MD^a ; Shanming Lu ; MD ; PhD^b ; Wenqin Zeng ; MD^c ; Shoucheng Xie^b ; Shengjun Xiao ; MD ; PhD^a ; ^{xiaoshengjun@glmc.edu.cn}
• 关键词：Breast carcinomas ; Clinically useful groups ; Immunohistochemistry ; GATA3 ; GCDFP15 ; Mammaglobin
• 刊名：Annals of Diagnostic Pathology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：26
• 期：Complete
• 页码：1-5
• 全文大小：786 K
• 卷排序：26

文摘

In this article, we adopt the latest clinically useful groups of breast carcinoma to detect the sensitivity of the novel marker GATA3 compared with the traditional markers GCDFP15 and MGB. We found that the GATA3 expression was not the same in the different clinically useful groups of breast carcinoma. In our study, GATA3 expression was superior to GCDFP and MGB in A and B groups of breast carcinoma. GATA3 expression poorly performed than GCDFP and MGB in C and D groups of breast carcinoma. We propose the careful selection of GATA3 for identifying hormone receptor negativity of breast cancer, especially in the case of TNBC.